Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Hormone Receptor Expression and Clinicopathologic Features in Male and Female Breast Cancer

  • Shandiz, Fatemeh Homaei (Radiation-Oncology, Solid Tumor Treatment Research Center, Mashhad University of Medical Sciences) ;
  • Tavassoli, Aliraz (Surgery, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences) ;
  • Sharifi, Nourieh (Pathology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences) ;
  • Khales, Sima Ardalan (Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, Mashhad University of Medical Sciences) ;
  • Kadkhodayan, Sima (Gynecology Oncology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences) ;
  • Khales, Sahar Ardalan (Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences)
  • Published : 2015.02.25
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Male and female breast cancers were investigated for variation in the clinicopathologic characteristics and expression of steroid hormone receptors in the northeast of Iran. Materials and Methods: Tumor specimens of 17 males and 338 females with breast cancer were collected at the hospitals of Mashhad University of Medical Sciences. Immunohistochemical expression of hormone receptors and clinicopathologic features of breast cancer were compared between two groups. Results: The mean age in men was 15 years higher than women (p=0.000). Males and females were mainly in stage II and III respectively (p=0.007). Although more than 60% of male and female patients were grade II, the respective figures for grade I and III were 25% and 12.5% in men but 7.1% and 27.2% in women respectively (p=0.025). ER was significantly more positive in men against women; 82.3% versus 53.4% (p=0.016). The related measures for PR was 58.8% and 50.3%, respectively (p=0.424). Males also showed significantly more ER expression than postmenopausal females; 82.3% versus 48.9% (p=0.010). Conclusions: Breast cancer in males and females contrasted in age at diagnosis, histological type, stage, grade and ER expression which emphasize they are separate diseases with different behaviors.

Keywords

References

  1. Anderson WF, Althuis MD, Brinton LA, Devesa SS (2004). Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat, 83, 77-86. https://doi.org/10.1023/B:BREA.0000010701.08825.2d
  2. Bowen RL, StebbingJ, Jones LJ (2006). A review of the ethnic differences in breast cancer. Pharmacogenomics, 7, 935-42. https://doi.org/10.2217/14622416.7.6.935
  3. Ciatto S, Iossa A, Bonardi R, Pacini P. (1990). Male breast carcinoma: review of a multicenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori, 76, 555-8.
  4. Dauda AM, Misauno MA, Ojo EO. (2011). Histopathological types of breast cancer in Gombe, North Eastern Nigeria: a seven-year review. Afr J Reprod Health, 15, 109-11.
  5. Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi, GN (2004). Breast carcinoma in men: a population-based study. Cancer, 101, 51-7. https://doi.org/10.1002/cncr.20312
  6. Gomez-Raposo C, Zambrana Tevar F, Sereno Moyano M (2010). Male breast cancer. Cancer Treat Reviews, 36, 451-75. https://doi.org/10.1016/j.ctrv.2010.02.002
  7. Grann VR, Troxel AB, Zojwalla NJ, et al (2005). Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer, 103, 2241-51. https://doi.org/10.1002/cncr.21030
  8. Greif JM, Pezzi CM, Klimberg VS, Bailey L, Zuraek M. (2012). Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol, 19, 3199-204. https://doi.org/10.1245/s10434-012-2479-z
  9. Homaei-Shandiz F, Ghavam-Nassiri MR, Sharifi N, et al (2006). Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer. Saudi Med J, 27, 1810-4.
  10. Micheli-Pellegrini V. (1975). Letter: More on lid-loading in the management of lagophthalmos. Plast Reconstr Surg, 55, 482. https://doi.org/10.1097/00006534-197555040-00016
  11. Moradi-Marjaneh M, Homaei-Shandiz F, Shamsian SAA, Eftekhar-Zadeh Mashhadi I (2008). Correlation of HER2/neu over expression, p53 protein accumulation and steroid receptor status with tumor characteristics: an Iranian study of breast cancer patients. Iran J Public Health, 37, 19-28.
  12. Mousavi SM, Gouya MM, Ramazani R, et al (2009). Cancer incidence and mortality in Iran. Ann Oncol, 20, 556-63.
  13. Mousavi SM, MontazeriA, Mohagheghi MA, et al (2007). Breast cancer in Iran: an epidemiological review. Breast J, 13, 383-91. https://doi.org/10.1111/j.1524-4741.2007.00446.x
  14. Ruddy KJ, Winer EP. (2013). Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol, 24, 1434-43. https://doi.org/10.1093/annonc/mdt025
  15. Vetto J, Jun SY, Paduch D, et al (1999). Stages at presentation, prognostic factors, and outcome of breast cancer in males. American J Surgery, 177, 379-83. https://doi.org/10.1016/S0002-9610(99)00067-7
  16. Wisinski KB, GW (2010). Male breast cancer . In W. and W. Harris JR, Lippman ME, Morrow M, Osborne CK Diseases of the Breast, 34thrd edition (4th ed., pp. 775-780). Philadelphia.
  17. Zygogianni AG, Kyrgias G, Gennatas C, et al (2012). Male breast carcinoma: epidemiology, risk factors and current therapeutic approaches. Asian Pac J Cancer Prev, 13, 15-9. https://doi.org/10.7314/APJCP.2012.13.1.015